Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.
|Articles|November 22, 2004
ACR meeting highlights new treatments for RA, gout
Gout was the subject of nearly 30 abstracts and the first plenary session in more than 20 years at the recent American College of Rheumatology (ACR) 2004 annual meeting held in San Antonio, Texas. The prevalence of gout, the most common form of arthritis in men older than 40, is increasing worldwide. Interest was strong also for a session on a new treatment for rheumatoid arthritis patients who respond inadequately to anti-TNF therapy.
Advertisement
Advertisement
Related to this article
Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.
In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
Advertisement
Advertisement